



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gotwals, et al.

Application No.: 10/625,260

Group Art Unit: 1644

Filed: July 22, 2003

Examiner: Maher M. Haddad, Ph. D.

Title: METHOD FOR THE TREATMENT OF FIBROSIS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

S I R:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56(a), applicants enclose herewith a copy of Form PTO-1449 listing United States patent documents relevant to the background of the invention described and claimed in the above-identified application. Also enclosed are copies of the non-United States patent/application references.

Applicants respectfully request that the Examiner consider the cited references in determining the patentability of the claimed invention. Applicants also request that the Examiner return a copy of enclosed Form PTO-1449 with initials or other marks indicating that the references have been so considered.

Respectfully submitted,

COLEMAN SUDOL SAPONE, P.C.

By: 

Kevin J. McGough
Reg. No. 31,279

Dated: December 10, 2004

714 Colorado Ave.
Bridgeport, Connecticut 06605-1601
203-366-3560

A076-USCN2

12/15/2004 WABDELRI 00000092 10625260

02 FC:1806 180.00 DP

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/625,260
Filing Date	July 22, 2003
First Named Inventor	Gotwals, et al.
Art Unit	1644
Examiner Name	Maher Haddad, Ph. D.
Attorney Docket Number	A073USCN2

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/625,260
		Filing Date	July 22, 2003
		First Named Inventor	Gotwals, et al.
		Art Unit	1644
		Examiner Name	Maher Haddad, Ph. D.
Sheet 2	of 3	Attorney Docket Number	A073USCN2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EG	Pappadopoulos, et al.; Verh. Dtsch. Ges. Path. 77, 292-295(1993) (Germany)	
	EH	Hokibara, et al., Clin. Exp. Immunol., 1998:114;236-44 (U.K.)	
	EI	Roy-Chaudhury, et al., Kidney International, Vol. 49(1996);pp.127-134 (U.S.)	
	EJ	Lin, et al., Current Opinion in Chem. Bio., vol. 2, no. 4, August 1998 (1998-08),pp.453-457(U.K.)	
	EK	Lobb, et al., Journ. Clin. Invest., vol. 94, no. 5, Nov. 1994(1994-11), pp.1722-1728	
	EL	Lobb, et al., European Resp. Journ., Supp., vol. 9, no. 22, August 1996 (1996-08)	
	EM	deFougerolles, et al., Journ. clin. Invest., vol. 105, no. 6 (March 2000), pp. 721-729	
	EN	Gardner, et al., Journ. Cell Science, 112, 263-272 (1999), pp. 263-272	
	EO	Gotwals, et al., Biochemistry 1999, 38, 8280-8288	
	EP	Pozzi, et al., Journ Cell Bio., Vol. 142, no. 2, July 27, 1998, 587-594	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/625,260
		Filing Date	July 22, 2003
		First Named Inventor	Gotwals, et al.
		Art Unit	1644
		Examiner Name	Maher Haddad, Ph. D.
Sheet 3	of 3	Attorney Docket Number	A073USCN2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EQ	Gardner, et al. Developmental Bio., 175, 301-313 (1996)	
	ER	Fiorucci, et al., Immunity, vol. 17, 769-780, December, 2002	
	ES	Kriegelstein, et al., Journ. Clin. Invest., December 2002, vol. 110, no. 12, pp. 1773-1782	
	ET	Briesewitz, et al., Journ. Bio. Chem., vol. 268, no. 4, February 5, 1993, pp. 2989-2996	
	EU	Fabri, et al., Tissue Antigens 1996: 48; 47-51	
	EV	Laffon, et al., Arthritis and Rheumatism, vol. 32, no. 4 (April 1989)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.